by drumbussward . Jan 24, 2013 11:21 PM . Permalink
Drumbussward Securities downgrades Star Scientific (STSI) from a strong sell to an urgent sell. This has been occasioned by shameful deceiving actions by Star management which should have clarified certain associations between consultants and institutions and itself and subsidiaries. The facts that when these deceiving actions were alleged and Star management remained silent have urged us to immediately downgrade Star as an investment. We also believe that Star management has a fiduciary duty to defend against scurrilous accusations of this nature as they are serious enough to invite legal investigations including those from governmental agencies. Such deceiving actions not only ruin the name of Star but also serve to devalue its assets. While clinical studies showed favorable results, details have not been disclosed. We believe that due to this scandal, release of such details in well-known medical journals will be subject to lengthy delays. In short, scandal over-rides science---at least for a while with devastating consequences for long suffering investors.
Accordingly, the stock will continue its strong downward trend. We forecast that the stock should easily break the $2.00 barrier and trade in the mid-ones for the near to intermediate term. We also believe that unless there is a fairly immediate management change, Star's stigma as a scamming outfit, a view shared among many investors, will become ingrained in the investor community and will be indeed difficult to turn around.
Investors holding Star stock should urgently sell at current levels and re-invest at much lower levels. New investors should follow suit in their buying decisions.
In the event that Star becomes delisted from the NASDAQ, we will immediately cease coverage of Star.
Dr. Drummond Bussward
Drumbussward Securities, Ltd.
REPORT FOR LIES AND SLANDER FROM FAKE ANALYST -- Keyword Search Drumbussward Securities
by drumbussward . Dec 28, 2012 1:34 AM . Permalink
Drumbussward Securities is initiating coverage of Star Scientific with a buy. The stock should be purchased at prices between $ 1 and $1.50. Incidentally this is where management and institutions now think the stock is fairly valued. We agree.
We see the stock recovering to the mid-twos by the end of 2013. Due to the heavy short interest, we also believe that a handsome fee loaning out these shares can be collected with little or no risk while we wait. After all, the CEO and his institutional friends are doing this so new investors can follow their lead.
Disclosure: within the next three months we will be seeking investment business from the company.
Analyst: Dr. Drummond Bussward